Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Kyorin
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Bronchitis, Chronic
Phase 2: Pneumonia, Mycoplasma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-205340 | P1 |
Completed |
Healthy Volunteers |
2017-03-31 |
|
| JapicCTI-153010 | P1 |
Unknown |
Healthy Volunteers |
2016-05-18 |
|
| JapicCTI-152913 | P3 |
Unknown |
Bronchitis, Chronic |
2016-05-01 |
|
| JapicCTI-152915 | P3 |
Unknown |
Bronchitis, Chronic |
2016-05-01 |